Kimia Biosciences Ltd Stock Price Today (NSE: KIMIABL)
Fundamental Score
Kimia Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kimia Biosciences Ltd share price today is ₹29.93, down 1.42% on NSE/BSE as of 7 August 2026. Kimia Biosciences Ltd (KIMIABL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹157.55 (Cr). The 52-week high for KIMIABL share price is ₹48.94 and the 52-week low is ₹23.20. At a P/E ratio of 21.20x, KIMIABL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 53.68% and a debt-to-equity ratio of 1.96.
Kimia Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance
Kimia Biosciences Ltd share price chart: -1.22% return over the past month. 52-week high ₹48.94, 52-week low ₹23.20.
Kimia Biosciences Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹32.25 | ₹32.50 | ₹30.99 | ₹31.00 | 4.31K (Cr) | |
| ₹31.60 | ₹32.25 | ₹31.60 | ₹31.68 | 296.00 (Cr) | |
| ₹31.49 | ₹31.93 | ₹30.20 | ₹31.61 | 5.21K (Cr) | |
| ₹32.00 | ₹32.50 | ₹31.00 | ₹31.00 | 30.01K (Cr) | |
| ₹32.25 | ₹32.50 | ₹30.65 | ₹31.01 | 2.92K (Cr) | |
| ₹31.26 | ₹32.89 | ₹31.26 | ₹31.47 | 206.00 (Cr) | |
| ₹32.68 | ₹32.70 | ₹32.10 | ₹32.10 | 1.21K (Cr) | |
| ₹32.53 | ₹32.53 | ₹31.62 | ₹31.90 | 2.90K (Cr) | |
| ₹34.99 | ₹34.99 | ₹33.44 | ₹34.33 | 2.01K (Cr) | |
| ₹32.53 | ₹33.43 | ₹32.52 | ₹33.28 | 286.00 (Cr) |
Kimia Biosciences Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹31.60 | ₹32.50 | ₹30.99 | ₹31.00 | -1.90% | |
| ₹32.08 | ₹34.99 | ₹30.00 | ₹31.61 | -1.47% | |
| ₹36.00 | ₹36.55 | ₹31.30 | ₹31.77 | -11.75% | |
| ₹35.35 | ₹38.36 | ₹33.02 | ₹36.50 | +3.25% | |
| ₹24.80 | ₹40.00 | ₹23.59 | ₹35.21 | +41.98% | |
| ₹34.50 | ₹34.50 | ₹23.20 | ₹23.55 | -31.74% | |
| ₹30.20 | ₹43.28 | ₹29.52 | ₹33.69 | +11.56% | |
| ₹33.00 | ₹36.50 | ₹28.50 | ₹30.44 | -7.76% | |
| ₹29.50 | ₹36.00 | ₹26.09 | ₹33.95 | +15.08% | |
| ₹32.89 | ₹37.97 | ₹28.40 | ₹29.40 | -10.61% | |
| ₹36.72 | ₹40.60 | ₹30.62 | ₹31.63 | -13.86% | |
| ₹37.62 | ₹39.20 | ₹34.25 | ₹36.00 | -4.31% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kimia Biosciences Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kimia Biosciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KIMIABL across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Return on Equity (53.68%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (25.09%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 21.20 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Cash Generation (₹29.32 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.94%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Profit Decline Concern (-81.41%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-28.87%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-2.84% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 1.96)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Limited Institutional Interest (FII+DII: 0.38%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kimia Biosciences Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kimia Biosciences Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Kimia Biosciences LtdKimia Bioscienc...Selected✓ KIMIABL • 530313 | 33.4/100 | ₹29.93₹30 | ₹157.55₹157.55 | 21.20Average 21.2 Average | 53.68%Excellent 53.68% Excellent | 25.09%Excellent 25.09% Excellent | 1.96Average 2.0 Average | 8.11%Good 8.11% Good | -2.84%Poor -2.84% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Kimia Biosciences Ltd Quarterly Performance
Latest quarterly metrics for KIMIABL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-28.87%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-81.41%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-2.84%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
8.11%
Compounded annual net profit growth over 5 years
Kimia Biosciences Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KIMIABL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Kimia Biosciences Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Kimia Biosciences Ltd (KIMIABL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Kimia Biosciences Ltd
About KIMIABL (Kimia Biosciences Ltd)
Kimia Biosciences Ltd is a dynamic pharmaceutical company dedicated to the innovation and production of high-quality Active Pharmaceutical Ingredients (APIs). With a strong foundat...ion in research and development, Kimia Biosciences is committed to addressing the evolving healthcare needs of a global market. The company operates with a focus on delivering reliable and cost-effective solutions to its partners, upholding stringent quality standards throughout its manufacturing processes. Kimia Biosciences strives to be a trusted source for essential pharmaceutical components, contributing to the development of life-enhancing medications and therapies that benefit patients worldwide. Kimia Biosciences Ltd specializes in synthesizing and distributing a diverse range of APIs that serve as the building blocks for various therapeutic treatments. Their extensive product portfolio encompasses APIs targeting prevalent health conditions, including cardiovascular diseases, metabolic disorders, and central nervous system ailments. The company is dedicated to expanding its API offerings to meet the demands of an ever-changing healthcare landscape. By focusing on both established and emerging therapeutic areas, Kimia Biosciences aims to provide comprehensive API solutions that empower pharmaceutical companies to formulate innovative and accessible medications. At the heart of Kimia Biosciences Ltd lies a steadfast commitment to quality and compliance. Their state-of-the-art manufacturing facilities adhere to the highest industry standards and are equipped with advanced technologies to ensure the consistent production of superior APIs. The company implements rigorous quality control measures at every stage of the manufacturing process, from sourcing raw materials to final product testing and packaging. Kimia Biosciences is dedicated to maintaining full transparency and traceability, providing customers with the assurance of safe, effective, and reliable APIs that meet global regulatory requirements.
Company Details
Key Leadership
KIMIABL Share Price: Frequently Asked Questions
What is the current share price of Kimia Biosciences Ltd?
Kimia Biosciences Ltd (KIMIABL) trades at ₹29.93 on NSE and BSE. Market cap ₹157.55 (Cr). Educational data only.
What is the P/E ratio of Kimia Biosciences Ltd?
Kimia Biosciences Ltd has a P/E of 21.20x vs industry average 34.89x.
What is the Bull Run score for Kimia Biosciences Ltd?
Kimia Biosciences Ltd has a Bull Run score of 33.4/100 based on 25+ financial parameters.
Does Kimia Biosciences Ltd pay dividends?
Kimia Biosciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Kimia Biosciences Ltd?
Kimia Biosciences Ltd has ROE of 53.68%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kimia Biosciences Ltd?
Kimia Biosciences Ltd has debt-to-equity of 1.96.
Is Kimia Biosciences Ltd a good investment?
Bull Run gives Kimia Biosciences Ltd a score of 33.4/100. This is not investment advice — consult a SEBI-registered advisor.